CytoDyn's Vision: a Paradigm-Shifting Therapeutic
CytoDyn's monoclonal antibody, Leronlimab, is being developed as a new treatment pathway for patients suffering from solid-tumor cancers
CytoDyn's Target: One Cellular Receptor, Many Implications
Our work centers on leronlimab, a monoclonal antibody CCR5 receptor antagonist, which could be used against many indications. Research has indicated that the CCR5 cellular receptor is implicated in a broad range of disease states. CytoDyn is focused on CCR5 and its role in the treatment of solid-tumor oncology. CCR5 appears to play multiple roles with implications in infection, tumor metastasis, and immune signaling.
Explore Our Science
About CytoDyn
CytoDyn is a publicly traded clinical stage biotechnology company developing innovative treatments utilizing leronlimab, a novel humanized monoclonal antibody that targets the CCR5 receptor. Leronlimab is being studied for its paradigm-shifting potential in solid-tumor oncology. The Company also strategically works with select partners to explore leronlimab’s potential benefits in certain inflammatory diseases. CytoDyn is committed to enhancing the lives of patients. Additional information about our Company and our development pipeline can be viewed at the links below.
Learn About CytoDyn Explore Our PipelineEmail Alerts
Stay informed and receive company updates straight to your inbox.